Cite

HARVARD Citation

    Ashina, M. et al. (2019). Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. pp. 1455-1464. [Online]. 
  
Back to record